HALO Halozyme Therapeutics Inc.

16.81
+0.2  (+1%)
Previous Close 16.61
Open 16.61
Price To Book 10.13
Market Cap 2430012298
Shares 144,557,543
Volume 1,003,469
Short Ratio
Av. Daily Volume 713,710

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 initiation announced October 31, 2017.
DARZALEX (Daratumumab) using ENHANZE
Amyloidosis
Primary endpoint was met March 2, 2017. Data released June 5, 2017 - HR 0.81. Disease-free-survival +0.9% over Herceptin.
Perjeta + Herceptin (APHINITY)
Adjuvant HER2+ breast cancer
Approval announced June 22, 2017.
Subcutaneous rituximab
Various blood cancers
Discontinued August 2016
PEGPH20 in Combination with docetaxel
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2H 2019.
HALO-301
Pancreatic cancer
Approved September 12, 2014.
HYQVIA
Subcutaneous treatment for patients with primary immunodeficiency (PI)
Phase 3 trial initiation announced July 26, 2018.
Subcutaneous Pertuzumab And Trastuzumab
HER2-positive early breast cancer
Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.
PEGPH20 and atezolizumab
Cholangiocarcinoma
Phase 1b/2 open label trial ongoing - noted January 9, 2019.
PEGPH20 and atezolizumab
Pancreatic cancer
PDUFA date 1Q 2019.
Trastuzumab (Herceptin) using ENHANZE
Breast cancer
Regulatory filing due 2H 2019.
DARZALEX (Daratumumab) using ENHANZE
Multiple myeloma

Latest News

  1. REPEAT/Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF
  2. Edited Transcript of HALO earnings conference call or presentation 21-Feb-19 9:30pm GMT
  3. Halozyme Therapeutics Inc (HALO) Q4 2018 Earnings Conference Call Transcript
  4. Halozyme Therapeutics (HALO) Reports Q4 Loss, Tops Revenue Estimates
  5. Halozyme Therapeutics: 4Q Earnings Snapshot
  6. Halo Labs Commences Trading on the OTCQB Venture Market in the United States under the Symbol AGEEF
  7. Halozyme Reports Fourth Quarter And Full-Year 2018 Results
  8. The Daily Biotech Pulse: Genomic Health Earnings, AbbVie's Humira Approved For Another Indication In Japan
  9. Halo Labs Reports Record Monthly Revenue of Approximately US$2.4 Million (CDN $3.1 Million) in January 2019
  10. Consolidated Research: 2019 Summary Expectations for Tenaris S.A, Rapid7, Halozyme Therapeutics, Cara Therapeutics, EnPro Industries, and K12 — Fundamental Analysis, Key Performance Indications
  11. Analysts Estimate Halozyme Therapeutics (HALO) to Report a Decline in Earnings: What to Look Out for
  12. Is Halozyme Therapeutics, Inc.’s (NASDAQ:HALO) CEO Pay Fair?
  13. See what the IHS Markit Score report has to say about Halozyme Therapeutics Inc.
  14. Halozyme To Host Fourth Quarter And Full-Year 2018 Financial Results Webcast And Conference Call
  15. Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
  16. argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE® Technology
  17. Alexion (ALXN) to Report Q4 Earnings: What's in the Cards?
  18. Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
  19. Today's Research Reports on Trending Tickers: Halozyme Therapeutics and Alnylam Pharmaceuticals